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Abstract
Background: Gefitinib, a small molecule tyrosine kinase inhibitor of the Epidermal Growth Factor Receptor (EGFR), has
shown limited efficacy in the treatment of lung cancer. Recognized clinical predictors of response to this drug, specifically
female, non-smoker, Asian descent, and adenocarcinoma, together suggest a genetic basis for drug response. Recent
studies have addressed the relationship between response and either sequence mutations or increased copy number of
specific receptor tyrosine kinases. We set out to examine the relationship between response and the molecular status
of two such kinases, EGFR and HER2, in 39 patients treated with gefitinib at the BC Cancer Agency.
Methods: Archival patient material was reviewed by a pathologist and malignant cells were selectively isolated by laser
microdissection or manual recovery of cells from microscope slides. Genomic DNA was extracted from 37 such patient
samples and exons 18–24, coding for the tyrosine kinase domain of EGFR, were amplified by PCR and sequenced. EGFR
and HER2 copy number status were also assessed using FISH in 26 samples. Correlations between molecular features
and drug response were assessed using the two-sided Fisher's exact test.
Results: Mutations previously correlated with response were detected in five tumours, four with exon 19 deletions and
one with an exon 21 missense L858R point mutation. Increased gene copy number was observed in thirteen tumours,
seven with EGFR amplification, three with HER2 amplification, and three with amplification of both genes. In our study
cohort, a correlation was not observed between response and EGFR mutations (exon 19 deletion p = 0.0889, we
observed a single exon 21 mutation in a non-responder) or increases in EGFR or HER2 copy number (p = 0.552 and 0.437,
respectively).
Conclusion: Neither mutation of EGFR nor increased copy number of EGFR or HER2 was diagnostic of response to
gefitinib in this cohort. However, validation of these features in a larger sample set is appropriate. Identification of
additional predictive biomarkers beyond EGFR status may be necessary to accurately predict treatment outcome.
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Background
Lung cancer is the leading cause of cancer-related death in
North America with 85% of patients eventually succumb-
ing to the disease [1]. The five year survival rate for this
cancer is low (16%) compared to other cancers [1] and
there exists a major need for additional therapeutic strate-
gies in its treatment. EGFR has been identified as a poten-
tial therapeutic target as overexpression is observed in 40–
80% late stage lung tumours and can confer a malignant
phenotype in cultured cells [2]. The FDA has approved the
use of two EGFR-targeted molecules, gefitinib ("Iressa"
from Astra Zeneca) and erlotinib ("Tarceva" from Genen-
tech/Roche) in the second- and third-line treatment of
lung cancer. Both of these drugs were designed to reversi-
bly bind the ATP-binding pocket of the EGFR tyrosine-
kinase domain, thereby inhibiting autophosphorylation
and stimulation of downstream signalling pathways
resulting in inhibition of proliferation, delayed cell cycle
progression, and increased apoptosis. In international
phase II trials, ~28% of Japanese patients responded to
gefitinib versus ~10% of patients of European descent as
assessed by symptom improvement and tumour shrink-
age [3,4]. These population-specific findings have sug-
gested that response to these drugs has a genetic
component although regional environmental factors have
not been discounted.
Somatic mutations in the EGFR tyrosine-kinase domain
have been correlated with reduced tumour size as a result
of treatment with gefitinib [5-9]. These mutations were
commonly found in patients fitting the responsive profile
observed in initial and subsequent clinical studies
[3,4,10], specifically female non-smokers of Asian
descent. In a review of sixteen studies, EGFR mutations
clustering around the tyrosine kinase domain ATP-bind-
ing pocket have been observed in 151 of 191 gefitinib
responders (79.1%) and 11 of 19 erlotinib responders
(57.9%) [11]. Confounding the model of mutation-medi-
ated drug response is the finding that 40 of 191 gefitinib
responders (20.9%) and 8 of 19 erlotinib responders
(42.1%) lack EGFR  mutations [11]. Conversely, EGFR
mutations were seen in 40 of 355 gefitinib non-respond-
ers (11.3%) and 16 of 117 erlotinib non-responders
(13.7%) [11] suggesting that somatic EGFR mutations are
neither necessary nor sufficient for response. This sugges-
tion is supported by the findings of a prospective trial of
gefitinib in which 4 of 16 patients selected for tumours
with EGFR mutations didn't respond to gefitinib [12]. An
increasing number of studies examining the tumours of
patients treated with gefitinib and erlotinib have corre-
lated increased EGFR gene copy number with response
[9,13,14]. Data analysis from a recent phase III trial of
erlotinib has supported these observations [15]. In this
trial, the response rate among patients with tumours with
amplification of EGFR was significantly higher than those
without this characteristic (20% vs. 2%) [15]. Multivariate
analysis revealed that only EGFR expression and increased
copy number were associated with erlotinib response and
no correlation between base-pair mutation and response
was found [15]. Increased HER2/Neu gene copy number
has also been associated with response, particularly in the
presence of increased EGFR copy number, EGFR overex-
pression or EGFR  mutation [14]. Other studies have
shown that tumours co-expressing HER2 and EGFR have
a poor prognosis [16,17] suggesting that there is a rela-
tionship between these genes that drives pathogenesis and
which may be targeted by gefitinib. Additional data are
needed to explore the ability of these molecular features
to predict response to EGFR-targeted tyrosine-kinase
inhibitors [18,19].
Recently we confirmed that Asian ethnicity still predicts
for response to gefitinib in a Canadian setting. We retro-
spectively analysed the experience of the Vancouver Can-
cer Centre in using gefitinib in a population in which 38%
of patients are of Asian descent [10]. To test previous cor-
relations of molecular features with response, we retro-
spectively analyzed diagnostic samples from this cohort of
patients for somatic EGFR  mutations as well as copy
number alterations in HER2 and EGFR.
Methods
Patient population & assessment response
Samples for molecular analysis were drawn from patients
who received gefitinib through the Extended Access Pro-
gram at the BC Cancer Agency as reported by Ho et al [10]
with ethics approval from the BC Cancer Agency Ethics
Review Board. The criteria for enrolment in the program
were the presence of histologically or cytologically con-
firmed locally advanced or metastatic NSCLC having
received prior standard systemic or radiation therapy or
being ineligible for standard treatment. Patients received
gefitinib following standard systemic or radiation therapy
and response was assessed radiographically according to
the SWOG modification of the WHO criteria [20]. In
brief, complete response (CR) was defined as a complete
disappearance of disease, partial response (PR) was
defined as a decrease of > 50% of the sum of the products
of the maximal perpendicular dimensions of measurable
lesions, stable disease (SD) was defined as the presence of
no new lesions or progression of current lesions, progres-
sive disease (PD) was defined as an increase of > 50% of
the sum of the products of the maximal perpendicular
dimensions of measurable lesions, the development of
new lesions, recurrence of lesions that had previously dis-
appeared or failure to return for evaluation because of
symptomatic deterioration.BMC Cancer 2007, 7:128 http://www.biomedcentral.com/1471-2407/7/128
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Laser microdissection and DNA extraction
To identify tumour cell populations for laser microdissec-
tion (LM) or manual scrape, malignant cells (cytology
specimens) or tissues (paraffin embedded biopsies) were
reviewed by a single reference pathologist. Because the
DNA extracted from formalin-fixed, paraffin-embedded
tissue blocks is of variable quality, the DNA from these
sources was characterized prior to microdissection. DNA
was extracted from a full 8 micron section of each block
using the "Laser-Microdissected Tissues" protocol of the
QIAamp spin-column kit (QIAgen, Valencia, CA). The
digestion volumes were increased five-fold and three final
30 uL elutions of TE (10:0.1) were performed. The DNA
was quantified by PicoGreen assay (Invitrogen, Carlsbad,
CA) and observed on a 2% agarose gel stained with ethid-
ium bromide. For a block to qualify for LM, the presence
of DNA fragments > 2000 bp was required (Figure 1). 40
archival samples from 37 patients were suitable for LM
and yielded enough DNA of sufficient quality for PCR and
sequencing.
Laser microdissection of pathologist-identified cells was
performed on serial sections of paraffin blocks using
either the Arcturus PixCell infra-red laser-capture or MMI
SLμCUT UV laser microdissection instruments. Dissected
cells were isolated onto the adhesive caps of 1.0 mL
microcentrifuge tubes (Arcturus) (Figure 2). Material from
cytology slides was scraped with a razor blade directly into
microcentrifuge tubes and DNA extracted as described
above.
PCR and sequencing of EGFR exons 18–24
Exons 18–24, coding for the tyrosine kinase domain of
EGFR, were amplified by PCR and sequenced. PCR prim-
ers were designed using human genome reference
sequence acquired from the UCSC Genome Browser
[21,22] (hg17_refGene_NM_005228). Primers were
designed to anneal within introns at least 40 bp away
from exon splice sites using the Primer3 program [23].
Sequencing tags were added to all PCR primers for down-
stream sequencing and experimentally optimized for
annealing temperature. The DNA sequence and annealing
temperatures (Tann) of all seven EGFR primer pairs are
listed in Table 1. PCR reactions were performed in 20 uL
and consisted of: 2.0 uL 10× Pfx Amplification Buffer
(Invitrogen), 0.4 uL 50 mM MgSO4 (Invitrogen), 0.4 uL
10 mM dNTPs (from 100 mM stock, Invitrogen), 1 uL
each of 10 uM forward and reverse primers (Invitrogen),
2.0 uL 10× PCRx Enchancer (Invitrogen), 0.1 uL 2.5 U/uL
Pfx Polymerase (Invitrogen) with 5–10 ng template and
distilled water added up to the final volume. Reactions
were cycled on an MJResearch Tetrad at 95 C for 5 minutes
followed by 35 cycles of 95 C for 30s Tann for 15s (Table
1), and 70 C for 2 minutes. PCR products were purified
using the Ampure magnetic-bead-based PCR product
purification system (Agencourt, Beverly, MA).
Sequencing of PCR products was performed with standard
chemistries in use by the production sequencing team at
the BC Cancer Agency Michael Smith Genome Sciences
Centre. Briefly, "forward" and "reverse" 1/24× reactions
contained 0.33 uL BigDye Ready Reaction Mix v3.1 (ABI),
0.4 uL 15× Big Dye Buffer (50% by volume Big Dye v3.1
Sequencing Buffer (ABI), 50% by volume Tris-EDTA),
0.02 uL distilled water, and 2 uL of purified PCR product.
Reactions were cycled 50 times with annealing tempera-
tures (Tann) appropriate to the forward and reverse
sequencing primers in use (96°C for 10s, Tann for 5s, 60°C
for 3 mins). All reactions were precipitated in a final con-
centration of 70% ethanol and 10 mM EDTA and spun at
2750 g for 30 minutes to pellet sequencing products. The
pellet was washed with 30 uL of 70% ethanol and air
dried before resuspension in 10 uL distilled water.
DNA of varying quality from formalin-fixed paraffin-embed- ded tissues Figure 1
DNA of varying quality from formalin-fixed paraffin-
embedded tissues. DNA extracted from tissue blocks is 
often degraded and chemically modified to varying degrees 
due to differences in fixation method and time, storage con-
ditions, and nature of the tissue. Diagnostic treatments such 
as fixation with Bouin's (samples 9–11) or acid decalcification 
(sample 12) can result in severely degraded template unusa-
ble for PCR. Little (sample 1) or moderately (sample 2–8) 
degraded templates can be used for PCR although additional 
input DNA may be necessary for robust PCR. To ensure that 
blocks with degraded DNA were not used in labour-inten-
sive microdissection, DNA from whole sections was 
extracted and qualified on a 2% agarose gel prior to micro-
dissection of additional sections. Blocks yielding highly 
degraded DNA were not used in this study.
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Sequencing reaction products were analyzed on auto-
mated ABI 3730XL sequencers and traces analyzed using
the Mutation Surveyor software package (SoftGenetics,
State College, PA) and the Phred/Phrap/Consed suite
[24,25]. All sequences were compared against human
genome sequence (NCBI accession NM_005228.3) to
identify mutations and polymorphisms. Observed known
polymorphisms recorded in the Single Nucleotide Poly-
morphism database (dbSNP) [26,27] were identified by
appropriate 'rs' number. To further validate results, PCR
and sequencing reactions were repeated for all samples in
which an apparent mutation was observed. Correlations
between clinical features and EGFR  mutations were
assessed using the two-sided Fisher's exact test.
Copy number analysis of EGFR and HER2
To assess EGFR and HER2 copy number, fluorescent in-
situ hybridization (FISH) was conducted using Pathvysion
EGFR and HER-2 DNA Probe kits (Vysis, Downers Grove,
IL). Formalin-fixed paraffin-embedded tissues were pre-
pared in serial 6 um sections on positively charged Color-
frost/Plus microscope slides (Fisher Scientific, Hampton,
NH). One section was H&E stained and tumour popula-
tions identified by a pathologist. Hybridization areas were
marked with a diamond-tipped pencil on the back of each
slide. Sections were incubated overnight at 56°C,
dewaxed by exposure to xylene for 10 minutes, dehy-
drated in 100% ethanol for 5 minutes, and air-dried 2–4
minutes on a slide warmer set to 37–45°C. The slides
were immersed in 0.2N HCl for 20 minutes, rinsed in
H2O for 10 minutes, and incubated in 1 M NaSCN pre-
treatment solution (Vysis) for 30 minutes at 80°C. After
rinsing with room temperature H2O for 3 minutes, sec-
tions were digested with pepsin (0.25 mg/mL in 0.01N
HCl) for 15–18 minutes at 37°C, and rinsed with room
temperature H2O for 5 minutes. Tissue morphology was
assessed by phase contrast microscopy to ensure sufficient
digestion of the collagen matrix. Slides were dehydrated
with two 4-minute treatments of 100% ethanol and air-
dried 2–4 minutes on a slide warmer set to 37–45°C. 2.5-
3 uL of the EGFR/CEP7 or HER2/CEP17 probe mixture
was applied to the hybridization area marked on the slide
and covered with a glass coverslip. Edges were sealed with
rubber cement. The slides were incubated at 73°C for 5
Table 1: PCR primers for 7 exons of the EGFR tyrosine kinase domain
Exon Annealing Tempera-
ture, °C (Tann)
Forward Primer 
Sequence
Reverse Primer 
Sequence
Product Length (with 
seq tags)
18 60 gtgtcctggcacccaagc ccccaccagaccatgaga 340
19 60 cagcatgtggcaccatctc cagagcagctgccagacat 273
20 60 cattcatgcgtcttcacctg catatccccatggcaaactc 412
21 60 agccataagtcctcgacgtg acccagaatgtctggagagc 372
22 56 tccagagtgagttaactttttcca ttgcatgtcagaggatataatgtaa 277
23 60 gaagcaaattgcccaagact atttctccagggatgcaaag 413
24 56 gcaatgccatctttatcatttc gctggcatgtgacagaacac 281
PCR primers were designed at least 40 bp from EGFR exons coding for the tyrosine kinase domain. Sequencing tags were added to each primer to 
allow sequencing of the PCR products. All forward primer sequences were prefixed with a -21M13 sequencing tag, TGTAAAACGACGGCCAGT. 
All reverse primer sequences were prefixed with an M13R sequencing tag, CAGGAAACAGCTATGAC. -21M13 and M13R sequencing primers 
were then used in the corresponding sequencing reaction to generate sequences from both strands of the PCR products.
Laser microdissection of mixed tumour & normal cell populations Figure 2
Laser microdissection of mixed tumour & normal cell populations. Tumour cells were microdissected using an MMI 
SLμCUT UV laser microdissection instrument to isolate tumour cells from surrounding normal tissue. A) Uncut lymph node 
tissue with metastatic tumour populations outlined in yellow. B) Normal stromal cells remaining after excision of tumour. C) 
Tumor cells isolated on adhesive cap.
AB CBMC Cancer 2007, 7:128 http://www.biomedcentral.com/1471-2407/7/128
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minutes then 37°C overnight to first co-denaturate the
probe and chromosomal DNA and then allow hybridiza-
tion. Rubber cemented coverslips were then removed and
the slides were placed in a post-hybridization wash solu-
tion (2× SSC, 0.3% NP-40) at 72°C for 2 minutes. After
rinsing the slides in 1× PBS, they were air-dried in the dark
for 30–60 minutes. 4 uL DAPI-1 counterstain (Vysis) was
applied to the hybridization area and coverslipped. FISH
analysis was performed by counting the number of signals
from each probe in forty tumour nuclei on each slide.
Two approaches were used to interpret raw FISH probe
counts and define gene amplification. In the first
approach, the total number of EGFR or HER2 signals was
divided by the total number of centromeric CEP7 or
CEP17 signals and a gene/CEP ratio reported for the pop-
ulation of forty cells. Samples with a gene/CEP ratio ≥ 2
were defined as displaying gene amplification. The second
approach applies published criteria [13] to raw FISH
counts to classify patients into six strata according to the
frequency of cells with specific gene copy numbers within
the tumour population. The six strata, as published [13]
and applied in our study, were: 1) disomy (≤2 copies in >
90% of cells); 2) low trisomy (≤2 copies in ≥40% of cells,
3 copies in 10% – 40% of the cells, ≥4 copies in < 10% of
cells); 3) high trisomy (≤2 copies in ≥40% of cells, 3 cop-
ies in ≥40% of cells, ≥4 copies in < 10% of cells); 4) low
polysomy (≥4 copies in 10% – 40% of cells); 5) high poly-
somy (≥4 copies in ≥40% of cells); and 6) gene amplifica-
tion (defined by presence of tight EGFR gene clusters and
a ratio of EGFR gene to chromosome of ≥2 or ≥15 copies
of EGFR  per cell in ≥10% of analyzed cells). The first
approach is commonly used in practical clinical assess-
ment of gene copy number and generally reflects the aver-
age copy number of the cell population examined. The
second approach attempts to capture the degree to which
gene amplification defines a cell population. While the
biological significance of the second method is unknown,
it has been shown to predict response in the case of gefit-
inib and increased EGFR copy number [13].
Results
Patient population
We previously documented the clinical characteristics of a
population of 61 patients treated with gefitinib at the BC
Cancer Agency between April 2002 and May 2004 [10]. In
the previous study of 61 patients, those with Asian ethnic-
ity and adenocarcinoma histology displayed a preferential
response to gefitinib. Diagnostic samples from 39 of these
individuals were suitable for microdissection and yielded
DNA of sufficient quality for PCR and sequencing and/or
copy number analysis by FISH. Microdissected materials
were used to avoid masking of cancer-specific features by
contaminating normal material. Figure 2 demonstrates
the heterogeneous nature of a metastatic tumour and the
ability of laser microdissection to separate tumour cells
from surrounding normal tissue. The patient subset con-
sisted of 23 females (59%), 17 patients of Asian descent
(44%), 12 non-smokers (31%), 34 tumours of adenocar-
cinoma subtype (87%), and a distribution between partial
response/stable disease/progressive disease of 6/14/17
(15%/33%/44%) and 2 patients lacking a response assess-
ment. The clinical characteristics and molecular status of
these patients are described in Supplemental Table 1  (see
Additional file 1).
EGFR tyrosine-kinase domain mutations
We studied the DNA sequence of the EGFR tyrosine kinase
domain in our patient samples as this domain was previ-
ously associated with increased gefitinib sensitivity [5-7].
In eight of thirty-eight tumours assessed we found ten
mutations, five of which have been previously correlated
with response (Figure 3). Four of these mutations were in-
frame deletions or substitutions within exon 19, all of
which impacted L747-A750 (Table 2) and retained the
ATP-binding lysine moiety. Two of these patients were
responsive to gefitinib, three were female, three were non-
smokers (the smoking status for the remaining patient
was unknown) and all four were of Asian descent. We
resequenced the normal tissue remaining after microdis-
section in two of these samples and found no mutations
suggesting that these mutations were specific to tumour,
consistent with previous reports. The fifth mutation was a
homozygous missense point mutation within exon 21
resulting in an L858R substitution (Table 3). This patient
was a female non-smoker of Asian descent that did not
respond to gefitinib. Three missense and two synonymous
point mutations were detected in exon 20, four of which
have been previously observed (Table 3). One of these
mutations was in a tumour from one of the drug respon-
sive patients that also had an exon 19 deletion. The exon
20 T790M mutation previously documented to confer
resistance to gefitinib [28] was not observed. The exon 20
point mutations we observed are unlikely to be artifactual
as previously postulated [29], as similar mutations were
not observed in any of the other amplicons we sequenced.
We were unable to validate the previously reported rela-
tionships between response and the presence of exon 19
mutations (p = 0.0889) or exon 21 mutations (we
observed a single mutation in a non-responder). If
patients exhibiting stable disease were counted among the
responders ("disease control"), correlation between exon
19 deletions and response was not observed (p = 1.00).
The presence of exon 19 mutations was correlated with
Asian ethnicity (p = 0.0207) and non-smoking status (p =
0.0406) but not with female gender (p = 0.633) or aden-
ocarcinoma histology (p = 1.00). When taken as a group,
there were no correlations with response and exon 20
mutations (p = 0.0889), female gender (p = 0.633), non-BMC Cancer 2007, 7:128 http://www.biomedcentral.com/1471-2407/7/128
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smoking status (p = 1.00), Asian ethnicity (p = 1.00), ade-
nocarcinoma subtype (p = 1.00), or disease control (p =
0.104).
EGFR Tyrosine-kinase Domain Polymorphisms
We detected two previously documented single nucleo-
tide polymorphisms (dbSNP rs10251977, rs17290643).
Exon 20 harbours the synonymous G/A SNP rs10251977
while exon 23 contains the synonymous SNP T/C
rs17290643. There was no correlation between these alle-
les and gefitinib response in our population.
EGFR & HER2 copy number analysis
Gene copy number was assessed in our patient tumour
samples as previous studies have shown a correlation
between copy number increases in EGFR  [9,13,15] or
HER2 [14] and gefitinib response. Two techniques were
used to interpret the FISH data for this analysis (Meth-
ods).
Increases in EGFR  copy number, defined as an EGFR/
CEP7 ratio ≥ 2.0, were observed in ten of twenty-six
tumours (Table 4). Of these ten, three also displayed
increased HER2 copy number (HER2/CEP17 ratio ≥ 2.0).
HER2 amplification in the absence of EGFR amplification
was seen in three additional tumours. Examples of the var-
ying degrees of amplification of these genes are shown in
Figure 4. Increased EGFR copy number did not correlate
with: the presence of mutation in either EGFR exon 19 (p
= 0.130) or exon 20 (p = 1.00); increased HER2 copy
number (p = 0.644); gender (p = 0.457); Asian ethnicity
(p = 0.688); smoking status (p = 0.380); adenocarcinoma
histology (p = 0.538); or response to gefitinib (p = 1.00).
When patients with stable disease are counted among the
responders ("disease control"), no correlation with
response was observed (p = 0.210). Likewise, increased
HER2 copy number did not correlate with: the presence of
mutation of either EGFR exon 19 (p = 1.00) or exon 20 (p
= 1.00); increased EGFR copy number (p = 0.644); gender
(p = 0.160); Asian ethnicity (p = 0.645); smoking status (p
= 0.351); adenocarcinoma histology (p = 1.00); or gefit-
inib response (p = 1.00) and disease control (p = 0.114).
Tumours were also stratified by EGFR  and HER2  copy
number using the criteria proposed by Cappuzzo et al
[13] (Table 4). Seven tumours were identified as FISH+ for
EGFR amplification and four tumours were identified as
FISH+ for HER2 amplification (high polysomy or gene
amplification). Only one of these tumours was FISH+ for
both EGFR and HER2 and this was the only sample to
meet the EGFR "gene amplification" criteria as proposed
by Capuzzo et al (10; ≥15 copies in ≥10% of cells). FISH+
status corresponded with an EGFR/CEP7 ratio ≥ 2.0 in
seven of ten samples. FISH+ status corresponded with a
HER2/CEP17 ratio ≥ 2.0 in four of six samples. There was
no correlation between EGFR FISH+ status and mutation
of either EGFR exon 19 (p = 0.0543) or exon 20 (p =
0.283); female gender (p = 0.378); Asian ethnicity (p =
1.00); smoking status (p = 1.00); adenocarcinoma histol-
ogy (p = 0.167); response to gefitinib (p = 0.552) or dis-
ease control (p = 0.653). Likewise, HER2 FISH+ did not
correlate with the presence of mutation of either EGFR
exon 19 (p = 1.00) or exon 20 (p = 0.544); increased EGFR
copy number (p = 1.00); gender (p = 0.593); Asian ethnic-
EGFR variant detection summary Figure 3
EGFR variant detection summary. The seven exons coding for the tyrosine kinase domain of EGFR were sequenced in 37 
tumours. Eight of these samples contained mutations, four with in-frame exon 19 deletions impacting L747-A750, four with a 
variety of exon 20 point mutations, and one with an exon 21 point mutation, L858R. Two previously documented synonymous 
polymorphisms were detected in this study, G2607A in exon 20 (rs10251977) and T2955C in exon 23 (rs17290643). Amino 
acid numbering is from the initial methionine residue of the EGFR protein isoform a (NCBI accession NP_005219).
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Table 2: EGFR exon 19 deletions/substitution
# Sex Ethnicity Smoking
Status
Source
Tissue
Response1 IKELREA TSPK a . a .
TCAAGGAATTAAGAGAAGCAACATCTCCGAAC D S
1 1F A s i a n U n k . L u n g P R T C A A---------------A A C A T C T C C G A A H e t *
22 M Asian N Lymph Node PD T C A A G G A A - - - - - C -------C A T C T C C G A AH e t
2 5F A s i a n N L u n g P D T C A A G G A A---------------T C T C C G A AD e l
6 6F A s i a n N L u n g P R T C A A---------------A A C A T C T C C G A A H e t *
Deletions of L747-A750 were detected in EGFR exon 19. All samples were classified as adenocarcinoma based on histology. Deleted bases are indicated by "-". In the case of patient #22, thirteen deleted bases were replaced by a single 
'C' thereby retaining the reading frame. In all cases, the ATP-binding residue K745 was retained. In the case of patients #11 and #66, a synonymous codon change results from the deletion (AAG > AAA) and the K745 ATP-binding 
residue is unchanged.
* = no mutations detected in normal tissue remaining after microdissection.
1 = response as measured radiographically and defined by SWOG modification of the WHO criteria.
PD = progressive disease, SD = stable disease, PR = partial response, Unk. = UnknownBMC Cancer 2007, 7:128 http://www.biomedcentral.com/1471-2407/7/128
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ity (p = 0.593); smoking status (p = 1.00); adenocarci-
noma histology (p = 0.408); response to gefitinib (p =
0.437) or disease control (p = 0.239).
Discussion
In DNA sequencing studies using patient samples, con-
taminating normal tissue has the potential to mask
tumour-specific features particularly in cases of highly
heterogeneous metastatic deposits. To examine somatic
features specific to tumours, we employed laser microdis-
section to isolate cancer cells from surrounding normal
tissue. The selectivity of this technique was demonstrated
by the identification of EGFR exon 19 deletions in the
tumour populations of two patient samples but not the
surrounding normal tissue remaining after microdissec-
tion.
In the evolving area of biomarkers predictive of response
to EGFR tyrosine kinase inhibitors, two hypotheses have
arisen, each claiming a specific alteration of EGFR is pre-
dictive of response. One hypothesis is that mutations
within the EGFR tyrosine kinase domain targeted by these
drugs are indicative of a capability to respond [5-7]. The
second hypothesis is that the presence of increased gene
copy number of EGFR or HER2 is a better predictor of
response [13-15]. When investigating the relevance of
these features to our own population of lung cancer
patients treated with gefitinib, our study detected all of
these features occurring both independently and coinci-
dentally in microdissected tumour cells.
Tumours from four of thirty-eight patients contained a
form of the exon 19 L747-A750 deletion and one tumour
harboured the exon 21 L858R point mutation. Two of the
patients with exon 19 deletions were responsive to gefit-
inib and were also found to have increased EGFR copy
number. In the remaining four responders, EGFR muta-
tions or gene amplifications that others previously corre-
lated with gefitinib response [5-7] were not observed.
These data are consistent with the notion that tumours
reliant on amplification of a mutant EGFR allele may be
particularly susceptible to inhibition by gefitinib. How-
ever, responders without apparent gefitinib-sensitising
EGFR  alterations may have shown characteristics of
response even without treatment or may have responded
due to an interaction between gefitinib and a protein
other than EGFR [30,31]. To identify alternative genetic
features mediating drug response, candidate genes influ-
enced by receptor tyrosine kinase inhibitors need to be
identified and studied in patients receiving these drugs.
In this study, we compared two methods of interpreting
FISH data and defining increased gene copy number. One
technique defined gene amplification as a gene/centro-
mere (e.g. EGFR/CEP7) threshold ≥ 2.0 while the second
technique defined "FISH+" status from the stratification
of different gene/centromere ratios into varying degrees of
polysomy [13]. While both of these methods identified
seven tumours with EGFR amplification, the EGFR/CEP7
ratio ≥ 2 method identified an additional three tumours
which were classified as "Low Polysomy" under the Cap-
puzzo criteria. While not originally designed for this pur-
pose, we also applied Cappuzzo's criteria [13] to our
HER2 FISH data. Again we saw an overlap of the samples
identified by both methods as having increased HER2
copy number. However, as with EGFR, the HER2/CEP17
ratio method identified samples not captured by the strat-
ification method but with ratios near the threshold of 2
for amplification. None of these patients responded to
gefitinib. These results suggest a need for further refine-
ment of criteria for defining amplification and may reflect
the ability of FISH to define precise copy number. Our
experience underscores the difficulty in capturing the het-
erogeneous nature of a tumour population with a single
Table 3: EGFR point mutations
# Sex Ethnicity Smoking
Status
Source 
Tissue
Response1 Exon CDS 
Mutation
Amino 
Acid
Previously 
Documented
44 F Asian N Pleura PR 20 G2549 > TT
C2691 > CT
S768I
L815L
[32–35]
none
11 F Asian Unk. Lung PR 20 G2566 > TT* V774L V774M [35, 36]
28 M Caucasian Y Brain SD 20 G2581 > AG G779S G779F [36]
35 F Caucasian Unk. Brain SD 20 G2703 > GA V819V [37]
47 F Asian N Lung SD 21 T2573 > GG L858R [5-7, 13, 15, 35, 38, 39]
Point mutations detected in EGFR exons 20 and 21. All samples were classified as adenocarcinoma based on histology. Point mutations altering 
V774 and G779 have been previously documented to result in amino acid substitutions different than those found in this study.
* = no mutations detected in normal tissue remaining after microdissection
1 = response as measured radiographically and defined by SWOG modification of the WHO criteria [20].
PD = progressive disease, SD = stable disease, PR = partial response, Unk. = UnknownB
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Table 4: EGFR and HER2 copy number alterations
# Sex Ethnicity Smoking
Status
Histology Source
Tissue
Block Type1 Response2 EGFR Mutation EGFR/CEP7 HER2/CEP17 EGFR
Stratification3
HER2
Stratification3
9 F Asian N adeno. Cerebellum Tissue Block SD Not Sequenced 2.1 1.9 High Poly. Low Poly.
11 F Asian Unk. adeno. Lung Tissue Block PR Exon 19 Del*, Exon 20 V774L 2.7 1.5 High Poly. High Trisomy
27 F Caucasian Y SCC Lung Tissue Block PD None 2.1 1.5 High Poly. Low Poly.
34 M Caucasian Y SCC Lung Tissue Block SD None 17.3 2.6 Gene Amp. High Poly.
36 M Asian Y adeno. Pleura Tissue Block SD None 2.0 2.0 Low Poly. Low Poly.
40 M Caucasian Y adeno. Pleura Cell Block SD None 3.1 1.4 High Poly. Low Poly.
42 M Caucasian Y adeno. Lymph Node Tissue Block Unk. None 2.1 2.3 Low Poly. High Poly.
43 F Caucasian Y adeno. Lymph Node Tissue Block PD None 2.7 0.9 High Poly. Low Trisomy
44 F Asian N adeno. Pleura Tissue Block PR Exon 20 S768I, Exon 20 L815L 1.9 2.9 Low Poly. High Poly.
56 M Caucasian Y adeno. Lung Tissue Block Unk. None 1.5 2.0 High Trisomy Low Poly.
57 M Caucasian Y adeno. Lymph Node Tissue Block SD None 1.6 2.2 Low Poly. High Poly.
64 F Caucasian Y
Pre Rx: adeno. Lymph Node Tissue Block - None 1.0 1.2 Low Trisomy High Trisomy
Post Rx: adeno. Pericaridium Tissue Block SD None 2.2 1.3 Low Poly. Low Trisomy
66 F Asian N adeno. Lung Tissue Block PR Exon 19 Del* 2.9 1.2 High Poly. Low Trisomy
Patient data provided for samples displaying increased EGFR or HER2 copy number (Probe/CEP ratio > 2.0) or identified as FISH+ (High Polysomy or Gene Amplification)
* = no mutations detected in normal tissue remaining after microdissection
1 = source of patient material (Tissue Block = microdissected formalin-fixed paraffin-embedded tissue block; Cell Block = whole section or microdissected formalin-fixed paraffin-embedded cell block; 
Cytology = scraped cytology slide)
2 = response as measured radiographically and defined by SWOG modification of the WHO criteria [20].
PD = progressive disease, SD = stable disease, PR = partial response, Unk. = Unknown
3 = Copy number stratification as proposed by Cappuzzo et al [13]. (Disomy = < 2 copies in > 90% of cells, Low Trisomy = ≤2 copies in ≥40% of cells, 3 copies in 10–40% of cells, ≥4 copies in < 10% 
of cells, High Trisomy = ≤2 copies in ≥40% of cells, 3 copes in ≥40% of cells, ≥4 copes in < 10% of cells, Low Polysomy: ≥4 copies in 10–40% of cells, High Polysomy = ≥4 copies in 40% of cells, Gene 
Amplification = ≥15 copies in ≥10% of cells)BMC Cancer 2007, 7:128 http://www.biomedcentral.com/1471-2407/7/128
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measurement. An understanding of the biological impli-
cations of EGFR gene amplification is needed to refine the
predictive specificity of these tests.
Conclusion
Recently, several studies have correlated gefitinib response
with either EGFR mutation [5-9] or increased EGFR copy
number [9,13-15] but the true predictive value of these
features is still under debate [18,19]. While we observed
EGFR DNA sequence mutations and increases in EGFR
and HER2 gene copy number in several of our specimens,
we were unable to statistically correlate the presence of
any of these molecular features with response. While these
findings may be due to a lack of statistical power due to
our small sample size, our study differs from others in our
use of a population with a large Asian component in a
North American setting. Even though EGFR status was not
a single predictive factor of drug response in our small
sample set, its assessment can increase the specificity of
selecting patients likely to respond to these drugs. To
improve the sensitivity of screening for potential respond-
ers, additional features other than EGFR that mediate drug
response need to be identified. Clinical criteria including
gender, histology, smoking status and ethnicity, are likely
to continue to play a role in the selection of patients for
treatment with the EGFR  tyrosine kinase inhibitors in
NSCLC as indirect surrogates for molecular features, until
completion of prospective clinical trials validating direct
predictive tests of tumour biology. Such trials should be
designed specifically to examine the utility of multiple
molecular predictors of response concurrently.
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